勃林格殷格翰品牌怎么样 申请店铺

我要投票 勃林格殷格翰在兽药行业中的票数:99 更新时间:2025-01-14
勃林格殷格翰是哪个国家的品牌?「勃林格殷格翰」是 上海勃林格殷格翰药业有限公司 旗下著名品牌。该品牌发源于德国,在1885年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
勃林格殷格翰怎么样

兽药十大品牌,始于1885年德国,集人用药品/动物保健/生物制药为一体,致力于人类生物制药化学和动物健康产品研发,专注于生猪/家禽/宠物/牛的疫苗和药品领域


勃林格殷格翰 (Boehringer-Ingelheim)是一家专注人类生物制药化学和动物健康产品的医药公司。包括了处方药和保健消费品。 是世界上颇大的私有制药企业。勃林格殷格翰是一家高度研发驱动的公司,始终专注药品的研究、开发、生产及推广。

勃林格殷格翰的核心业务是人用药品,包括处方药、自主保健品和工业客户业务 (生物制药、药品生产和药用化学品)。勃林格殷格翰出产的药品一直被认为是治疗呼吸、心血管、中枢神经系统疾病及代谢紊乱、传染病的标杆。主要的研究领域包括免疫、肿瘤方面的适应症,目前多个具有治疗价值潜力的活性成分已经研发出来了。

勃林格殷格翰于1994年正式进入中国市场,目前在华投资总额超过2亿欧元,公司管理总部位于上海,业务遍布全国,拥有员工约3500名。勃林格殷格翰中国近年来发展迅速,包括人用药品、动物保健、生物制药3大业务板块并驾齐驱,协调发展,推动公司持续增长。


The top ten brand of veterinary medicine, started in 1885 in Germany, integrates human medicine / animal health care / biopharmaceutical as a whole, devotes to the research and development of human biopharmaceutical chemistry and animal health products, and focuses on the vaccine and drug field of pigs / Poultry / pets / cattle. Boehringer Ingelheim is a pharmaceutical company focusing on human biopharmaceutical chemistry and animal health products. It includes prescription drugs and health care consumer goods. It is a quite large private pharmaceutical enterprise in the world. Boehringer Ingelheim is a highly R & D driven company, which has always focused on the research, development, production and promotion of drugs. The core business of Boehringer Ingelheim is human drugs, including prescription drugs, independent health care products and industrial customer business (biopharmaceutical, pharmaceutical production and pharmaceutical chemicals). The drugs produced by Boehringer Ingelheim have been regarded as the benchmark for the treatment of respiratory, cardiovascular, central nervous system diseases, metabolic disorders and infectious diseases. The main research fields include immune and tumor indications. At present, a number of active ingredients with therapeutic potential have been developed. Boehringer Ingelheim officially entered the Chinese market in 1994. At present, the total investment in China is more than 200 million euros. The company's management headquarters is located in Shanghai, with businesses all over the country and about 3500 employees. In recent years, Boehringer Ingelheim has developed rapidly in China, including three business sectors of human drugs, animal health care and biopharmaceuticals, which are in line with each other, coordinated development and promoted the company's sustained growth.

本文链接: https://brand.waitui.com/a19fcecbe.html 联系电话:400-820-5970,800-820-5970

千城特选小程序码

7×24h 快讯

12306:将在条件允许的热门方向和时段加大运力资源投放

36氪获悉,截至13日17时,铁路12306已累计发售春运期间车票8507万张,其中通过学生、务工人员预约购票服务专区兑现学生优惠票383.7万张、务工人员车票112.4万张,通过购票信息预填优化试点专区兑现车票25.9万张,通过候补购票兑现车票673.9万张,铁路部门根据12306预售票和候补购票数据,将在条件允许的热门方向和时段加大运力资源投放。

2小时前

美股大型科技股盘前普跌,英伟达跌超2%

36氪获悉,美股大型科技股盘前普跌,截至发稿,特斯拉、英伟达跌超2%,奈飞、亚马逊、苹果跌近1%,谷歌跌0.65%,微软跌0.48%,Meta跌0.37%。

2小时前

热门中概股美股盘前多数下跌,网易涨超4%

36氪获悉,热门中概股美股盘前多数下跌,截至发稿,小鹏汽车跌超2%,理想汽车、腾讯音乐跌超1%,蔚来跌0.96%,爱奇艺跌0.53%,阿里巴巴跌0.37%,京东跌0.21%;网易涨超4%,百度涨0.26%。

2小时前

紫光国微:2024年净利润同比下降52.99%

36氪获悉,紫光国微披露2024年度业绩快报,营业收入55.11亿元,同比下降27.26%;归属于上市公司股东的净利润11.91亿元,同比下降52.99%。报告期末,公司财务状况良好,归属于上市公司股东的所有者权益124.06亿元,较报告期初增加6.42%,资产负债率26.39%,较报告期初下降6.71个百分点。主要系特种集成电路业务下游需求不足,产品出货量减少导致营业收入下降,以及公司保持高强度研发投入导致利润下滑。

2小时前

永辉金山万达店“学习胖东来”自主调改1月10日开业,为上海首家

36氪获悉,1月10日,永辉超市上海首家“学习胖东来”自主调改店在金山区的金山万达广场开业。截至开业当天,永辉在全国的调改店数量达到了36家。据了解,永辉超市金山万达店在商品方面进行了大幅调整。店内原有的13358支商品,下架了9418个单品,随后新增商品6753支,新增商品比例超过63%,调整后的商品结构接近胖东来商品结构的80%,进口商品占比达20%。此外,调改后,金山万达店员工的工资平均增幅约30%,员工和储备学员人数也有一定增长。

2小时前

本页详细列出关于成康药业的品牌信息,含品牌所属公司介绍,成康药业所处行业的品牌地位及优势。
咨询